Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995
Phase 2b TULIP study readout in August 2014, new Lipoprotein(a) study approved

Naarden, The Netherlands, 8 July 2014 - Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, today announced the approval of a phase 1 pilot study in subjects with isolated, elevated Lipoprotein(a) (Lp(a)), for which additional funding has been secured.

read more